An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
The prevalence of osteoporosis and sarcopenia is significantly higher in patients with liver disease than in those without liver disease and osteoporosis and sarcopenia negatively influence morbidity and mortality in liver disease, yet these musculoskeletal disorders are frequently overlooked in clinical practice for patients with chronic liver disease. The objective of this review is to provide a comprehensive understanding of the molecular mechanisms of musculoskeletal disorders accompanying the pathogenesis of liver disease. The increased bone resorption through the receptor activator of nuclear factor kappa (RANK)-RANK ligand (RANKL)-osteoprotegerin (OPG) system and upregulation of inflammatory cytokines and decreased bone formation through increased bilirubin and sclerostin and lower insulin-like growth factor-1 are important mechanisms for osteoporosis in patients with liver disease. Sarcopenia is associated with insulin resistance and obesity in non-alcoholic fatty liver disease, whereas hyperammonemia, low amount of branched chain amino acids, and hypogonadism contributes to sarcopenia in liver cirrhosis. The bidirectional crosstalk between muscle and bone through myostatin, irisin, β-aminoisobutyric acid (BAIBA), osteocalcin, as well as the activation of the RANK and the Wnt/β-catenin pathways are associated with osteosarcopenia. The increased understandings for these musculoskeletal disorders would be contributes to the development of effective therapies targeting the pathophysiological mechanism involved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 3×
“Further, both EWGSOP2 and AWGS recognize entirely impaired muscle mass, muscle strength, and muscle function as diagnostic criteria for severe sarcopenia [95,96].”
BackgroundWnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · cited 2×
“RANKL and OPG are members of the TNF superfamily and are crucial for the regulation of bone resorption [51].”
BackgroundCellular and molecular mechanisms of bone remodeling
Raggatt, L. J., & Partridge, N. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.041087 · Cited by 1,402 · cited 1×
“Bone remodeling is tightly regulated by osteocytes and osteoblasts through different cytokines and hormones modulating the activation, resorption, reversal, formation, and termination phase [50].”
BackgroundSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 1×
“As a result of sclerostin expression, the Wnt receptor is blocked and glycogen synthase kinase 3 phosphorylates β-catenin, which is involved in ubiquitination and degradation through the proteasome pathway [81].”
BackgroundGlutamine: Metabolism and Immune Function, Supplementation and Clinical Translation
Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., & Newsholme, P. (2018) · Nutrients · doi:10.3390/nu10111564 · Cited by 1,261
Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation
Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., & Newsholme, P. (2018) · doi:10.20944/preprints201809.0459.v1 · Cited by 1,261
The key role of anaplerosis and cataplerosis for citric acid cycle function
Owen, O. E., Kalhan, S. C., & Hanson, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r200006200 · Cited by 1,172
Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102
Osteocytes, mechanosensing and Wnt signaling
Bonewald, L. F., & Johnson, M. L. (2008) · Bone · doi:10.1016/j.bone.2007.12.224 · Cited by 1,076
Insulin resistance: review of the underlying molecular mechanisms
Yaribeygi, H., Farrokhi, F. R., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27603 · Cited by 929
Interleukin-6 Is an Essential Regulator of Satellite Cell-Mediated Skeletal Muscle Hypertrophy
Serrano, A. L., Baeza-Raja, B., Perdiguero, E., Jardí, M., & Muñoz-Cánoves, P. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.011 · Cited by 873
Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models
Schiaffino, S., & Mammucari, C. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-4 · Cited by 816
IL-6-induced skeletal muscle atrophy
Haddad, F., Zaldivar, F., Cooper, D. M., & Adams, G. R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01026.2004 · Cited by 612
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608 · cited 1×
“Therefore, sarcopenia was observed almost half of patients with liver cirrhosis, and negatively influenced the mortality and prognosis of liver disease [3,9].”
BackgroundWang, X., Hu, Z., Hu, J., Du, J., & Mitch, W. E. (2006) · Endocrinology · doi:10.1210/en.2006-0251 · Cited by 600
The contribution of bone to whole-organism physiology
Karsenty, G., & Ferron, M. (2012) · Nature · doi:10.1038/nature10763 · Cited by 537
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440 · cited 2×
“, 2017 [102] Association between sarcopenia and histological severity of NAFLD Prospective cross-sectional study 309 patients (including 240 biopsy proven NAFLD patients) BIA Sarcopenia was significantly associated with NASH (OR 2.”
BackgroundInfluentialSelf-citationHong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385 · cited 8×
“Studies on Patients with Liver Cirrhosis (LC) Author, Year Study Aim Study Design Study Population Method to Diagnosis Sarcopenia Outcome Montano-Loza et al., 2012 [106] Incidence of sarcopenia, association between sarcopenia and mortality and prognosis in LC patients Prospective study 112 patients with LC L3 skeletal…”
BackgroundInfluentialCockayne, S., Adamson, J., Lanham-New, S., Shearer, M. J., Gilbody, S., & Torgerson, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.12.1256 · Cited by 361
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
Drummond, M. J., Dreyer, H. C., Fry, C. S., Glynn, E. L., & Rasmussen, B. B. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91397.2008 · Cited by 322
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125915 · Cited by 314
Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo
Axmann, R., Böhm, C., Krönke, G., Zwerina, J., Smolen, J., & Schett, G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24781 · Cited by 263 · cited 1×
“Experimental studies revealed that IL-6 was associated with disrupted osteogenesis of bone marrow stem cells in osteoporosis models, and suppression of the IL-6 receptor prevented osteoclast-mediated bone resorption [60,61].”
BackgroundDankbar, B., Fennen, M., Brunert, D., Hayer, S., Frank, S., Wehmeyer, C., Beckmann, D., Paruzel, P., Bertrand, J., Redlich, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3917 · Cited by 262
Development of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251
Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation
Hamaguchi, Y., Kaido, T., Okumura, S., Fujimoto, Y., Ogawa, K., Mori, A., Hammad, A., Tamai, Y., Inagaki, N., & Uemoto, S. (2014) · Liver Transplantation · doi:10.1002/lt.23970 · Cited by 242
Bone disorders in chronic liver disease
Collier, J. (2007) · Hepatology · doi:10.1002/hep.21852 · Cited by 238
β-aminoisobutyric Acid, l-BAIBA, Is a Muscle-Derived Osteocyte Survival Factor
Kitase, Y., Vallejo, J. A., Gutheil, W., Vemula, H., Jähn, K., Yi, J., Zhou, J., Brotto, M., & Bonewald, L. F. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.041 · Cited by 219
Polyzos, S. A., & Margioris, A. N. (2018) · Hormones · doi:10.1007/s42000-018-0049-x · Cited by 212
Kim, G., Lee, S., Lee, Y., Jun, J. E., Ahn, J., Bae, J. C., Jin, S., Hur, K. Y., Jee, J. H., Lee, M., et al. (2018) · Hepatology · doi:10.1002/hep.30049 · Cited by 198
de Kam, D., Smulders, E., Weerdesteyn, V., & Smits-Engelsman, B. C. M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0938-6 · Cited by 185
Monegal, A., Navasa, M., Guañabens, N., Peris, P., Pons, F., Martinez de Osaba, M. J., Ordi, J., Rimola, A., Rodés, J., & Muñoz-Gómez, J. (2001) · Osteoporosis International · doi:10.1007/s001980170094 · Cited by 183
Zhao, B., Grimes, S. N., Li, S., Hu, X., & Ivashkiv, L. B. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111566 · Cited by 182
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
Menon, K. V. N., Angulo, P., Weston, S., Dickson, E. R., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00144-1 · Cited by 180 · cited 18×
“%) with advanced PBC and PSC have osteopenic bone disease, and risk factors for hepatic osteopenia are low BMI, older age, postmenopausal status, the presence of muscle wasting, high ALP, and low serum albumin.”
BackgroundInfluentialGuañabens, N., Parés, A., Ros, I., Caballería, L., Pons, F., Vidal, S., Monegal, A., Peris, P., & Rodés, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.035 · Cited by 179
Dole, N. S., Mazur, C. M., Acevedo, C., Lopez, J. P., Monteiro, D. A., Fowler, T. W., Gludovatz, B., Walsh, F., Regan, J. N., Messina, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.115 · Cited by 173
Zhang, C., McFarlane, C., Lokireddy, S., Bonala, S., Ge, X., Masuda, S., Gluckman, P. D., Sharma, M., & Kambadur, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2079-7 · Cited by 158
Schiefke, I. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i12.1843 · Cited by 156 · cited 12×
“Studies on Patients Who Underwent Liver Transplantation Author, Year Study Aim Study Design Study Population Method to Diagnosis Osteoporosis Outcome Guichelaar et al., 2006 [35] To identify the prevalence and predictive factors for low bone mass before OLT, Posttransplant bone loss, and bone gain at the lumbar spine…”
BackgroundInfluentialGolds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Guañabens, N., Cerdá, D., Monegal, A., Pons, F., Caballería, L., Peris, P., & Parés, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.016 · Cited by 142
Bone disease in patients with primary sclerosing cholangitis
Angulo, P., Grandison, G. A., Fong, D. G., Keach, J. C., Lindor, K. D., Bjornsson, E., & Koch, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.014 · Cited by 133
Synthesis of IL-6 by Hepatocytes Is a Normal Response to Common Hepatic Stimuli
Norris, C. A., He, M., Kang, L.-I., Ding, M. Q., Radder, J. E., Haynes, M. M., Yang, Y., Paranjpe, S., Bowen, W. C., Orr, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096053 · Cited by 132 · cited 1×
“As IL-6 increases during liver injury to stimulate liver regeneration, upregulated IL-6 could affect bone remodeling in various types of liver disease [62,63].”
BackgroundSelf-citationOsteoporosis in chronic liver disease
Guañabens, N., & Parés, A. (2018) · Liver International · doi:10.1111/liv.13730 · Cited by 128 · cited 6×
“The presence of osteoporosis in patients with liver disease adversely affects their clinical outcomes in terms of quality of life, survival, and liver-related complications, regardless of etiology and severity [1,2].”
BackgroundInfluentialWang, Y.-J., Wang, Y., Zhan, J.-K., Tang, Z.-Y., He, J.-Y., Tan, P., Deng, H.-Q., Huang, W., & Liu, Y.-S. (2015) · International Journal of Endocrinology · doi:10.1155/2015/482940 · Cited by 126
Osteoporosis in liver disease: Pathogenesis and management
Handzlik-Orlik, G., Holecki, M., Wilczyński, K., & Duława, J. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816641351 · Cited by 114
Bone diseases in patients with chronic liver disease
Jeong, H., & Kim, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174270 · Cited by 113 · cited 6×
“For the nutritional support of the patient with osteoporosis, persistent calcium intake at a dosage of 1000 to 1500 mg/day as well as oral 25-hydroxy vitamin D supplementation of 400–800 IU/day or 260 μg every 2 weeks is recommended [2].”
BackgroundSelf-citationLi, X., Zhou, Z.-Y., Zhang, Y.-Y., & Yang, H.-L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154677 · Cited by 89 · cited 1×
“Experimental studies revealed that IL-6 was associated with disrupted osteogenesis of bone marrow stem cells in osteoporosis models, and suppression of the IL-6 receptor prevented osteoclast-mediated bone resorption [60,61].”
BackgroundGonzalez-Calvin, J. L., Gallego-Rojo, F., Fernandez-Perez, R., Casado-Caballero, F., Ruiz-Escolano, E., & Olivares, E. G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0077 · Cited by 81
Estradiol metabolism in cirrhosis
Zumoff, B., Fishman, J., Gallagher, T. F., & Hellman, L. (1968) · Journal of Clinical Investigation · doi:10.1172/jci105709 · Cited by 80 · cited 1×
“Because the bone protective effect of these estrogens is weak, it is not enough to overcome post-menopausal osteoporosis in women and liver-disease related osteoporosis in men [92,93].”
BackgroundRuiz-Gaspà, S., Martinez-Ferrer, A., Guañabens, N., Dubreuil, M., Peris, P., Enjuanes, A., de Osaba, M. J. M., Alvarez, L., Monegal, A., Combalia, A., et al. (2010) · Hepatology · doi:10.1002/hep.24605 · Cited by 75
Bering, T., Diniz, K. G. D., Coelho, M. P. P., Vieira, D. A., Soares, M. M. S., Kakehasi, A. M., Correia, M. I. T. D., Teixeira, R., Queiroz, D. M. M., Rocha, G. A., et al. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12269 · Cited by 73
Kirk, B., Mooney, K., Amirabdollahian, F., & Khaiyat, O. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00445 · Cited by 72
Rainer, F., Horvath, A., Sandahl, T. D., Leber, B., Schmerboeck, B., Blesl, A., Groselj‐Strele, A., Stauber, R. E., Fickert, P., Stiegler, P., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14474 · Cited by 65
Guerra-Menéndez, L., Sádaba, M. C., Puche, J. E., Lavandera, J. L., de Castro, L. F., de Gortázar, A. R., & Castilla-Cortázar, I. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-271 · Cited by 64
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
Filip, R., Radzki, R., & Bieńko, M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s170533 · Cited by 60
DiGirolamo, D. J., Singhal, V., Chang, X., Lee, S.-J., & Germain-Lee, E. L. (2015) · Bone Research · doi:10.1038/boneres.2014.42 · Cited by 56
Osteoporosis in primary biliary cholangitis
Danford, C. J., Trivedi, H. D., Papamichael, K., Tapper, E. B., & Bonder, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3513 · Cited by 56
Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment
de la Garza, R. G., Morales-Garza, L. A., Martin-Estal, I., & Castilla-Cortazar, I. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2761w · Cited by 55 · cited 1×
“In end-stage liver disease, hepatocellular dysfunction and reduced GH receptors lead to low serum IGF-1 levels, subsequently causing osteoporosis [87].”
BackgroundKim, G., Kim, K. J., Rhee, Y., & Lim, S.-K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182202 · Cited by 38
Wei, M. T., Le, A. K., Chang, M. S., Hsu, H., Nguyen, P., Zhang, J. Q., Wong, C., Wong, C., Cheung, R., & Nguyen, M. H. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25433 · Cited by 28
Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography
Zheng, J.-P., Miao, H.-X., Zheng, S.-W., Liu, W.-L., Chen, C.-Q., Zhong, H.-B., Li, S.-F., Fang, Y.-P., & Sun, C.-H. (2018) · Medicine · doi:10.1097/md.0000000000010645 · Cited by 28
Bone-Muscle Crosstalk: Unraveling New Therapeutic Targets for Osteoporosis
Picca, A., Calvani, R., Manes-Gravina, E., Spaziani, L., Landi, F., Bernabei, R., & Marzetti, E. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170526112300 · Cited by 23
Cited by
Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease
Musio, A., Perazza, F., Leoni, L., Stefanini, B., Dajti, E., Menozzi, R., Petroni, M. L., Colecchia, A., & Ravaioli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087517 · Cited by 26
“Evidence indicated that fragility fractures of osteoporosis were 2.5-fold more common in subjects with NAFLD [279,280]; furthermore, low BMD was more relevant in patients with progressive liver disease, including NASH, and significant fibrosis [279,281].”
BackgroundInfluentialJadzic, J., Milovanovic, P., Tomanovic, N., Zivkovic, V., Djukic, D., Nikolic, S., Djuric, M., & Djonic, D. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02130-3 · Cited by 11
Baumgartner, M., Lischka, J., Schanzer, A., de Gier, C., Walleczek, N.-K., Greber-Platzer, S., & Zeyda, M. (2022) · Nutrients · doi:10.3390/nu14102133 · Cited by 9
Kuo, S.-J., Chen, C.-L., Chen, S.-H., & Ko, J.-Y. (2023) · Life · doi:10.3390/life13071438 · Cited by 7
Metadata
- Authors
- Yang, Y. J., & Kim, D. J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-05
- Volume
- 22
- Issue
- 5
- Pages
- 2604
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3135006797
- Cited by
- 112
- References
- 69
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.